So, we resystematically reviewed the latest randomized controlled trials (RCTs) to comprehensive assessment for the efficacy and safety of TGP plus HCQ compared to HCQ treatment, thereby aiding clinical decision‐making in the therapy of pSS. This evidence concerns the gene TGM4 and peeling skin syndrome.